Demonstrating Fibrosis Regression Through Non-Invasive Assessments in the Ph2b SYMMETRY Trial of Efruxifermin: Advancing Development in Compensated Cirrhosis Due to MASH
- Evaluating changes in multiple non-invasive tests to assess fibrosis regression and disease improvement, enabling more comprehensive treatment monitoring and supporting development in advanced MASH populations
- Leveraging longitudinal non-invasive assessment approaches to characterize therapeutic impact over time, improving understanding of disease modification and strengthening clinical decision-making
- Generating evidence of improvement across measures associated with advanced liver disease to support development strategies, enabling greater confidence in therapeutic benefit and improving future patient outcomes